AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...
Guardant Health, Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive ...
Liquidia fit this approach well. Their launch may go down as one of the most successful drug launches ever. They have already taken 25% market share and are effectively expanding the market. Amazingly ...
Arquitos returned 82.1% net of fees and expenses in 2025, compared to 12.8% for the Russell 2000. Read more here.
Zacks Investment Research on MSN
Here's how Eli Lilly's oncology drugs are poised ahead of Q4 earnings
While Eli Lilly LLY is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro (for diabetes) and ...
ImmunityBio has skyrocketed in recent weeks, and today’s losses could be down to profit taking. In January alone, the company ...
Although everyone is waiting for Abel's first stock purchase as CEO, it's his selling activity that could leave an indelible ...
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback